The HTG EdgeSeq Pan B-Cell Lymphoma Panel is a research-use only panel to measure gene expression of mRNA targets commonly associated with indolent and aggressive lymphomas to help identify lymphoma subgroups to elucidate the transcription response of disease state and drug therapy. With 298 gene targets, it addresses the heterogeneity of B-Cell lymphomas, including published signatures and drug targets. Leveraging the sensitivity and dynamic range of next-generation sequencing (NGS), the HTG EdgeSeq Pan B-Cell Lymphoma Panel enables multiplex profiling from limited formalin-fixed, paraffin-embedded (FFPE) samples. This extraction-free HTG EdgeSeq assay is automated on the HTG EdgeSeq system.
Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Mediastinal B Cell Lymphoma, Multiple Myeloma
CD20 (Membrane Spanning 4-Domains A1)
Next-Generation Sequencing (NGS)